EUVIMEDEUVIMED entdecken
Crossref

Parallel Analyses by Mass Spectrometry (MS) and Reverse Phase Protein Array (RPPA) Reveal Complementary Proteomic Profiles in Triple‐Negative Breast Cancer (TNBC) Patient Tissues and Cell Cultures

Nan Wang, Yiying Zhu iD, Lianshui Wang, Wenshuang Dai, Taobo Hu iD, Zhentao Song, Xia Li, Qi Zhang, Jianfei Ma, Qianghua Xia, Jin Li, Yiqiang Liu und 2 weitere

PROTEOMICS · 2025

DOI: 10.1002/pmic.202400107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PROTEOMICS, 2025. Verfasst von Nan Wang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Mills Institute for Personalized Cancer Care, Fynn Biotechnologies Ltd, Jinan, Shandong Province, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Proteomics, Protein Array Analysis, Proteome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: FynnBio R&D funds.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High‐plex proteomic technologies have made substantial contributions to mechanism studies and biomarker discovery in complex diseases, particularly cancer. Despite technological advancements, inherent limitations in individual proteomic approaches persist, impeding the achievement of comprehensive quantitative insights into the proteome. In this study, we employed two widely used proteomic technologies, mass spectrometry (MS) and reverse phase protein array (RPPA) to analyze identical samples, aiming to systematically assess the outcomes and performance of the different technologies. Additionally, we sought to establish an integrated workflow by combining these two proteomic approaches to augment the coverage of protein targets for discovery purposes. We used 14 fresh frozen tissue samples from triple‐negative breast cancer (TNBC: seven tumors versus seven adjacent non‐cancerous tissues) and cell line samples to evaluate both technologies and implement this dual‐proteomic strategy. Using a single‐step protein denaturation and extraction protocol, protein samples were subjected to reverse‐phase liquid chromatography (LC) followed by electrospray ionization (ESI)‐mediated MS/MS for proteomic profiling. Concurrently, identical sample aliquots were analyzed by RPPA for profiling of over 300 proteins and phosphoproteins that are in key signaling pathways or druggable targets in cancer. Both proteomic methods demonstrated the expected ability to differentiate samples by groups, revealing distinct proteomic patterns under various experimental conditions, albeit with minimal overlap in identified targets. Mechanism‐based analysis uncovered divergent biological processes identified with the two proteomic technologies, capitalizing on their complementary exploratory potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsProteomicsProtein Array AnalysisProteomeHumansFemaleCell Line, TumorTandem Mass SpectrometryChromatography, Reverse-PhaseMass SpectrometryBiomarkers, Tumor

Stichwörter der Autor:innen

fresh frozen tissuelabel‐free mass spectrometryliquid chromatographyreverse phase protein arraytriple‐negative breast cancer

Substanzen

ProteomeBiomarkers, Tumor

Autor:innen und Institutionen

  • Mills Institute for Personalized Cancer Care, Fynn Biotechnologies Ltd, Jinan, Shandong Province, China.
  • Department of Chemistry, Tsinghua University, Beijing, China.
  • Department of Breast Surgery, Peking University People's Hospital, Beijing, China.
  • Department of Bioinformatics, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
  • Department of Cell Biology, 2011 Collaborative Innovation Center of Tianjin for Medical Epigenetics, Tianjin Medical University, Tianjin, China.
  • Department of Pathology, Peking University Cancer Hospital, Beijing, China.

ORCID-Profile: Yiying Zhu, Taobo Hu, Zhiyong Ding

Förderung

  • FynnBio R&D funds

Zitieren

APA

Wang, N., Zhu, Y., Wang, L., Dai, W., Hu, T., Song, Z., Li, X., Zhang, Q., Ma, J., Xia, Q., Li, J., Liu, Y., Long, M., & Ding, Z. (2025). Parallel Analyses by Mass Spectrometry (MS) and Reverse Phase Protein Array (RPPA) Reveal Complementary Proteomic Profiles in Triple‐Negative Breast Cancer (TNBC) Patient Tissues and Cell Cultures. PROTEOMICS. https://doi.org/10.1002/pmic.202400107

Vancouver

Wang N, Zhu Y, Wang L, Dai W, Hu T, Song Z, et al. Parallel Analyses by Mass Spectrometry (MS) and Reverse Phase Protein Array (RPPA) Reveal Complementary Proteomic Profiles in Triple‐Negative Breast Cancer (TNBC) Patient Tissues and Cell Cultures. PROTEOMICS. 2025. doi:10.1002/pmic.202400107

BibTeX
@article{Wang2025,
  author = {Wang, Nan and Zhu, Yiying and Wang, Lianshui and Dai, Wenshuang and Hu, Taobo and Song, Zhentao and Li, Xia and Zhang, Qi and Ma, Jianfei and Xia, Qianghua and Li, Jin and Liu, Yiqiang and Long, Mengping and Ding, Zhiyong},
  title = {Parallel Analyses by Mass Spectrometry (MS) and Reverse Phase Protein Array (RPPA) Reveal Complementary Proteomic Profiles in Triple‐Negative Breast Cancer (TNBC) Patient Tissues and Cell Cultures},
  journal = {PROTEOMICS},
  year = {2025},
  doi = {10.1002/pmic.202400107}
}
Kostenlos starten →